You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.



Virtual Case Challenges in Spondyloarthritis

  • Authors: Abhijeet Danve, MD, MHS; Atul Deodhar, MD
  • CME / ABIM MOC Released: 11/30/2022
  • Valid for credit through: 11/30/2023
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.00 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for rheumatologists and primary care physicians.

The goal of this activity is that learners will be better able to diagnose and manage patients with spondyloarthritis (SpA) through virtual case simulations.

Upon completion of this activity, participants will:

  • Demonstrate improved performance associated with:
    • Ordering appropriate tests and assessments for patients with SpA
    • Providing appropriate recommendations regarding follow-up care for patients with SpA
    • Selecting appropriate therapy for patients with SpA


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


  • Abhijeet Danve, MD, MHS

    Assistant Professor of Medicine
    Yale School of Medicine
    New Haven, Connecticut


    Abhijeet Danve, MD, MHS, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Amgen; Janssen; Novartis
    Speaker or member of speakers bureau for: AbbVie; Amgen
    Research funding from: Eli Lilly; Novartis

  • Atul Deodhar, MD

    Professor of Medicine
    Medical Director, Rheumatology Clinics
    Medical Director, Immunology Infusion Center
    Oregon Health & Science University
    Portland, Oregon


    Atul Deodhar, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Amgen; Aurinia; Bristol Myers Squibb Company; Celgene; GlaxoSmithKline; Janssen; Lilly; MoonLake; Novartis; Pfizer; UCB
    Speaker or member of speakers bureau for: Janssen; Novartis; Pfizer; UCB
    Research funding from: AbbVie; Bristol Myers Squibb Company; Celgene; GlaxoSmithKline; Lilly; Novartis; Pfizer; UCB


  • Karen Badal, MD, MPH

    Senior Medical Education Director, Medscape, LLC


    Karen Badal, MD, MPH, has no relevant financial relationships.

  • Terra Sumstine

    Writer, Chichester Associates Inc.


    Terra Sumstine has no relevant financial relationships.

Compliance Reviewer

  • Yaisanet Oyola, MD

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Yaisanet Oyola, MD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Virtual Case Challenges in Spondyloarthritis

Authors: Abhijeet Danve, MD, MHS; Atul Deodhar, MDFaculty and Disclosures

CME / ABIM MOC Released: 11/30/2022

Valid for credit through: 11/30/2023



  1. Mease PJ. Suspecting and diagnosing the patient with spondyloarthritis and what to expect from therapy. Med Clin North Am. 2021;105:325-339.
  2. Magrey MN, Danve AS, Ermann J, et al. Recognizing axial spondyloarthritis: a guide for primary care. Mayo Clin Proc. 2020;95:2499-2508.
  3. Rudwaleit M, Landewé R, van der Heijde D, et al. The development of Assessment of SpondyloArthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777-783.
  4. Poddubnyy D, Jadon DR, Van den Bosch F, et al. Axial involvement in psoriatic arthritis: an update for rheumatologists. Semin Arthritis Rheum. 2021;51:880-887.
  5. Helliwell PS. Axial disease in psoriatic arthritis. Rheumatology (Oxford). 2020;59:1193-1195.
  6. Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2019;71:1285-1299.
  7. Coates LC, Corp N, van der Windt DA, et al. GRAPPA treatment recommendations: 2021 Update. J Rheumatol. 2022;49(6 Suppl 1):52-54.
  8. Baraliakos X, Gossec L, Pournara E, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis. 2021;80:582-590.
  9. Adalimumab [Prescribing Information]. Approved 2002. Revised February 2021.
  10. Certolizumab [Prescribing Information]. Approved 2008. Revised March 2019.
  11. Etanercept [Prescribing Information]. Approved 1998. Revised December 2012.
  12. SIMPONI (golimumab) [Prescribing Information]. Approved 2009. Revised September 2019.
  13. SIMPONI ARIA (golimumab) [Prescribing Information]. Approved 2009. Revised February 2021.
  14. Infliximab [Prescribing Information]. Approved 1998. Revised October 2021.
  15. Ixekizumab [Prescribing Information]. Approved 2016. June 2021.
  16. Secukinumab [Prescribing Information]. Approved 2015. Revised January 2016.
  17. Tofacitinib [Prescribing Information]. Approved 2012. Revised May 2018.
  18. Upadacitinib [Prescribing Information]. Approved 2019. Revised October 2022.
  19. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. US Food and Drug Administration. September 1, 2021. Accessed September 2, 2022.
  20. Landewé R, van Tubergen A. Clinical Tools to Assess and Monitor Spondyloarthritis. Curr Rheumatol Rep. 2015;17:47.
« Return to: Virtual Case Challenges in Spondyloarthritis
  • Print